Back to search

Article

Investigating Neural Dysfunction with Abnormal Protein Deposition in Alzheimer’s Disease Through Magnetic Resonance Spectroscopic Imaging, Plasma Biomarkers, and Positron Emission Tomography

2023-04-25

Abstract excerpt

In Alzheimer’s disease (AD), aggregated abnormal proteins induce neuronal dysfunction. Despite the evidence supporting the association between tau proteins and brain atrophy, further studies are needed to explore their link to neuronal dysfunction in the human brain. To clarify the relationship between neuronal dysfunction and abnormal proteins in AD-affected brains, we conducted magnetic resonance spectroscopic i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
17ac487e-a464-5d5c-887b-f1a7a480990d
DOI
10.1101/2023.04.23.23288989
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Investigating Neural Dysfunction with Abnormal Protein Deposition in Alzheimer’s Disease Through Magnetic Resonance Spectroscopic Imaging, Plasma Biomarkers, and Positron Emission TomographyDOI 10.1101/2023.04.23.23288989
Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseasesSemantic proximity
Development and Clinical Validation of Global Tau Severity Score in Young- and Late- Onset Alzheimer's Disease Using Florzolotau (18F) PETSemantic proximity
Medial temporal lobe Tau-Neurodegeneration <i>mismatch</i> from MRI and plasma biomarkers identifies vulnerable and resilient phenotypes with ADSemantic proximity
Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes Using Alzheimer's Disease Biofluid, PET, Postmortem Pathology Biomarkers, and APOE Genotype.Semantic proximity
Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.Semantic proximity
Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes using Alzheimer’s Disease Biofluid, PET, Postmortem Pathology Biomarkers and APOE GenotypeSemantic proximity
Florzolotau (18F) PET provides in-vivo measures of tau pathology in progressive supranuclear palsy: An imaging-postmortem correlation studySemantic proximity
Fluid and Neuroimaging Biomarkers in Microgliopathy Colony-Stimulating Factor-1 Receptor-Related DisordersSemantic proximity
Comparison of variables associated with cerebrospinal fluid neurofilament, total‐tau, and neurograninSemantic proximity
In vivo PET classification of tau pathologies in patients with frontotemporal dementiaSemantic proximity
Investigating the Role of Neuroinflammation and Brain Clearance in Frontotemporal Lobar Degeneration using 7T MRI and Biofluid Markers: Protocol for an observational cross-sectional cohort studySemantic proximity
From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias.Semantic proximity
Select a neighboring publication to make it the new centre.